Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form
Problem login in? Contact us
OK

News

February 10, 2014
South Korean regenerative medicine company Medipost announced the clinical study results of usage ’Pneumostem’ for chronic pulmonary disease treatment in premature babies. to be published in international academic journal ‘The Journal of Pediatrics’ (Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial)
Read more
February 18, 2014
Mirna Therapeutics, Inc., US private biotechnology company focused on the development and commercialization of micro-RNA based therapeutics, announces scientific publication in PLOS ONE journal (In-Depth Analysis Shows Synergy between Erlotinib and miR-34a) that suggests enhanced potency of lead therapeutic MicroRN-34 in Combination with FDA Approved lung cancer drug erlotinib (Tarceva®) based on in vitro studies.
Read more
February 18, 2014
The randomized, double-blind study is the Company’s second cancer therapy approved for clinical trials by FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The Company’s patient-specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer.
Read more
February 24, 2014
N.V. (Nasdaq:TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, announced the commencement of a proposed underwritten public offering of 5,125,000 ordinary shares by TMG Holdings Coöperatief U.A., an affiliate of Warburg Pincus LLC. Tornier will not sell any ordinary shares in this offering or receive any proceeds from this offering.
Read more
February 24, 2014
Preliminary analysis shows patient cartilage regrowth within 3 months
Read more
May 13, 2014
Deep Knowledge Ventures, a firm that focuses on age-related disease drugs and regenerative medicine projects, says the program, called VITAL, can make investment recommendations about life sciences firms by poring over large amounts of data.
Read more
AGING ANALYTICS – INVEST FOR LIFE
info@aginganalytics.com
AGING ANALYTICS 2016